These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 23940081

  • 21. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer.
    Baumgart A, Seidl S, Vlachou P, Michel L, Mitova N, Schatz N, Specht K, Koch I, Schuster T, Grundler R, Kremer M, Fend F, Siveke JT, Peschel C, Duyster J, Dechow T.
    Cancer Res; 2010 Jul 01; 70(13):5368-78. PubMed ID: 20551051
    [Abstract] [Full Text] [Related]

  • 22. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.
    Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D, Creighton CJ, Slingerland JM.
    Oncogene; 2015 Jun 11; 34(24):3107-19. PubMed ID: 25151964
    [Abstract] [Full Text] [Related]

  • 23. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
    Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY.
    Cancer Res; 2006 Oct 15; 66(20):10100-11. PubMed ID: 17047074
    [Abstract] [Full Text] [Related]

  • 24. Sox2 expression involvement in the oncogenicity and radiochemoresistance of oral cancer stem cells.
    Chou MY, Hu FW, Yu CH, Yu CC.
    Oral Oncol; 2015 Jan 15; 51(1):31-9. PubMed ID: 25456004
    [Abstract] [Full Text] [Related]

  • 25. Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation.
    Cai YR, Zhang HQ, Qu Y, Mu J, Zhao D, Zhou LJ, Yan H, Ye JW, Liu Y.
    Oncol Rep; 2011 Oct 15; 26(4):877-85. PubMed ID: 21687954
    [Abstract] [Full Text] [Related]

  • 26. Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway.
    Li D, Zhao LN, Zheng XL, Lin P, Lin F, Li Y, Zou HF, Cui RJ, Chen H, Yu XG.
    Mol Med Rep; 2014 Dec 15; 10(6):3169-76. PubMed ID: 25310235
    [Abstract] [Full Text] [Related]

  • 27. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
    Kondo S, Iwata S, Yamada T, Inoue Y, Ichihara H, Kichikawa Y, Katayose T, Souta-Kuribara A, Yamazaki H, Hosono O, Kawasaki H, Tanaka H, Hayashi Y, Sakamoto M, Kamiya K, Dang NH, Morimoto C.
    Clin Cancer Res; 2012 Nov 15; 18(22):6326-38. PubMed ID: 23037767
    [Abstract] [Full Text] [Related]

  • 28. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM.
    Cancer Res; 2005 Feb 15; 65(4):1459-70. PubMed ID: 15735034
    [Abstract] [Full Text] [Related]

  • 29. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M, He CS, Wei SH, Zhang L.
    Eur J Cancer; 2013 Nov 15; 49(16):3559-72. PubMed ID: 23916913
    [Abstract] [Full Text] [Related]

  • 30. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
    Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB.
    Cancer Res; 2006 Jun 01; 66(11):5542-8. PubMed ID: 16740687
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.
    Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S, Haber DA.
    Elife; 2015 Feb 16; 4():. PubMed ID: 25686219
    [Abstract] [Full Text] [Related]

  • 32. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.
    Clin Cancer Res; 2011 Apr 15; 17(8):2260-9. PubMed ID: 21220474
    [Abstract] [Full Text] [Related]

  • 33. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
    Li Y, Chen K, Li L, Li R, Zhang J, Ren W.
    Tumour Biol; 2015 Dec 15; 36(12):9823-8. PubMed ID: 26159849
    [Abstract] [Full Text] [Related]

  • 34. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 15; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 35. Long Noncoding RNA LBCS Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2.
    Chen X, Xie R, Gu P, Huang M, Han J, Dong W, Xie W, Wang B, He W, Zhong G, Chen Z, Huang J, Lin T.
    Clin Cancer Res; 2019 Feb 15; 25(4):1389-1403. PubMed ID: 30397178
    [Abstract] [Full Text] [Related]

  • 36. Sex-Determining Region Y-box 2 Promotes Growth of Lung Squamous Cell Carcinoma and Directly Targets Cyclin D1.
    Li C, He B, Huang C, Yang H, Cao L, Huang J, Hu C.
    DNA Cell Biol; 2017 Apr 15; 36(4):264-272. PubMed ID: 28151013
    [Abstract] [Full Text] [Related]

  • 37. NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma.
    Xiao ZJ, Liu J, Wang SQ, Zhu Y, Gao XY, Tin VP, Qin J, Wang JW, Wong MP.
    Elife; 2017 Jul 24; 6():. PubMed ID: 28737489
    [Abstract] [Full Text] [Related]

  • 38. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer.
    Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, Markowitz D, Reisfeld RA, Luo Y.
    Br J Cancer; 2011 Apr 26; 104(9):1410-7. PubMed ID: 21468047
    [Abstract] [Full Text] [Related]

  • 39. Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11.
    Wang X, Chen Y, Wang X, Tian H, Wang Y, Jin J, Shan Z, Liu Y, Cai Z, Tong X, Luan Y, Tan X, Luan B, Ge X, Ji H, Jiang X, Wang P.
    Cancer Res; 2021 Oct 15; 81(20):5217-5229. PubMed ID: 34385181
    [Abstract] [Full Text] [Related]

  • 40. Lung Tumor Suppressor GPRC5A Binds EGFR and Restrains Its Effector Signaling.
    Zhong S, Yin H, Liao Y, Yao F, Li Q, Zhang J, Jiao H, Zhao Y, Xu D, Liu S, Song H, Gao Y, Liu J, Ma L, Pang Z, Yang R, Ding C, Sun B, Lin X, Ye X, Guo W, Han B, Zhou BP, Chin YE, Deng J.
    Cancer Res; 2015 May 01; 75(9):1801-14. PubMed ID: 25744720
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.